|1.||Wang, Rui: 2 articles (02/2012 - 09/2009)|
|2.||Hsueh, Po-Ren: 2 articles (12/2007 - 01/2005)|
|3.||Choi, Su-Mi: 1 article (04/2013)|
|4.||Park, Sun Hee: 1 article (04/2013)|
|5.||Lee, Seok: 1 article (04/2013)|
|6.||Cho, Byung-Sik: 1 article (04/2013)|
|7.||Kim, Hee-Je: 1 article (04/2013)|
|8.||Eom, Ki-Seong: 1 article (04/2013)|
|9.||Kim, Si-Hyun: 1 article (04/2013)|
|10.||Kwon, Jae-Cheol: 1 article (04/2013)|
08/01/2002 - "In the present study, we examined the bone tissue penetration of isepamicin at a dose of 15 mg/Kg, and the results were correlated to microbiologic data to estimate the clinical efficacy of isepamicin in bone infections. "
06/01/1995 - "The results of this study indicate that treatment with isepamicin once daily is effective and well tolerated in hospitalised adults with various infections."
11/01/2012 - "Isepamicin, an old aminoglycoside, may play a role in the treatment of patients with infections caused by those multi-drug resistant pathogens. "
02/01/2012 - "We sought to review the potential role of isepamicin against infections with contemporary Gram-negative bacteria. "
08/01/1997 - "Effects of combination use of a second generation cephem and an aminoglycoside antibiotic isepamicin (ISP), for the treatment of post-surgical infections of the lower digestive tract were examined from a laboratory and clinical perspective. "
|2.||Urinary Tract Infections (Urinary Tract Infection)
09/01/1990 - "To assess the usefulness of single dose treatment with isepamicin (ISP) against chronic complicated urinary tract infection (CC-UTI), laboratory and clinical studies were carried out. "
09/01/1990 - "[Pharmacokinetic and clinical studies on isepamicin in chronic complicated urinary tract infection using daily single dose treatment]."
06/01/1999 - "Once daily isepamicin treatment in complicated urinary tract infections."
09/01/1986 - "[Clinical trial of HAPA-B in complicated urinary tract infections]."
09/01/1986 - "HAPA-B was administered intramuscularly to 20 patients with complicated urinary tract infections to evaluate its clinical effects and safety in conformity with the estimations of efficacy of antimicrobial agents standardized by the UTI Committee. "
|3.||Respiratory Tract Infections (Respiratory Tract Infection)
11/01/1995 - "The administration regimen of isepamicin in patients with chronic respiratory tract infection."
11/01/1995 - "A total of 34 patients with intractable chronic respiratory tract infections were treated with isepamicin and/or piperacillin in different dosage regimens. "
06/01/1995 - "Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of acute lower respiratory tract infections caused by gram-negative organisms."
11/01/1986 - "[Comparison of HAPA-B and amikacin in the treatment of respiratory tract infections]."
06/01/1995 - "In the patients receiving 8 mg/kg isepamicin, 40 out of 41 patients with urinary tract infections were considered cured or improved as were 8/10 patients with lower respiratory tract infections, 1/3 patients with skin infections and 1/2 patients with intra-abdominal infections. "
07/01/1999 - "Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study."
06/01/1995 - "A study of patients with nosocomial pneumonia had an additional treatment arm of isepamicin 7.5 mg/kg twice daily. "
07/01/1999 - "A population approach was used to determine isepamicin pharmacokinetics in 196 intensive care unit patients treated for nosocomial pneumonia with isepamicin and a broad-spectrum beta-lactam. "
06/01/1995 - "For patients with nosocomial pneumonia, the proportions of patients in the intent-to-treat population (n = 130) who were clinically cured at the end of treatment were similar in each treatment group: 18/44 (41%) isepamicin once daily; 19/45 (42%) isepamicin twice daily; and 17/41 (42%) amikacin. "
06/01/1995 - "In this prospective, randomised, open trial, the safety and efficacy of intravenous administration of isepamicin was compared with that of intravenous amikacin in seriously ill adults with nosocomial pneumonia or septicaemia. "
02/01/2000 - "In this study we compared the efficacy and safety of isepamicin versus amikacin at a dose of 7.5 mg/kg i.v. q12h for 10-14 days in children with pyelonephritis. "
02/01/2000 - "Isepamicin versus amikacin for the treatment of acute pyelonephritis in children."
02/01/2000 - "Isepamicin was shown to be as effective and safe as amikacin in the treatment of children with pyelonephritis and might prove an advantageous alternative in areas with high incidence of resistance to other aminoglycosides."
|5.||Anti-Infective Agents (Microbicides)
|1.||Hip Replacement Arthroplasty (Total Hip Replacement)
|5.||Renal Dialysis (Hemodialysis)